Clovis Oncology Announces First Quarter 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Clovis Oncology (CLVS) PT Raised to $74 at RBC Capital
May 9, 2018 8:18 AM EDTRBC Capital raised its price target on Clovis Oncology (NASDAQ: CLVS) to $74.00 (from $73.00) while maintaining an Outperform rating.
Analyst Kennen MacKay commented, "We continue to like CLVS as they launch Rubraca in 2L maintenance OC despite a crowded landscape given a potential... More
Clovis Oncology (CLVS) Misses Q1 EPS by 18c
May 8, 2018 4:27 PM EDTClovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($1.54), $0.18 worse than the analyst estimate of ($1.36). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $18.33 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More